Biofrontera Inc

Capital Structure and Liquidity Biofrontera has a current ratio of 1.52, indicating that it has $1.52 in current assets for every $1 of current liabilities. The company's liquidity position is assessed as low, with cash and equivalents amounting to $6.39 million against total liabilities of $18.08 million. The debt-to-equity ratio of 0.44 suggests a relatively conservative capital structure, with long-term debt of $4.59 million compared to total equity of $10.48 million. ### Profitability and Returns The company reported a net loss of $10.54 million for the period, with an operating loss of $11.35 million. Return on equity (ROE) is negative at -100.53%, and return on assets (ROA) is also negative at -36.89%, indicating poor profitability relative to its equity and asset base. These metrics fall significantly below the industry median for profitability in the pharmaceutical sector, which typically sees positive ROE and ROA figures. ### Segments and Geographic Exposure Biofrontera's revenue is concentrated in a single product line, Ameluz, which is used in photodynamic therapy for skin conditions. The company's geographic exposure is primarily in the United States, where Ameluz is marketed and sold. There is no disclosed international revenue, suggesting a high concentration risk in the U.S. market. ### Growth Trajectory The company's revenue for the period was $41.71 million. While this represents a positive figure, the operating and net losses indicate that the company is not yet profitable. Analysts have provided a mean price target of $6.00, with a median of $6.00 and a high of $9.00, suggesting a cautious but not overly optimistic outlook. ### Risk Factors The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating cash flow of $13.36 million and free cash flow of $10.40 million suggest ongoing cash burn, which could become a concern if not addressed through additional financing or improved operational performance. ### Recent Events Recent filings and transcripts do not indicate any major events that would significantly impact the company's financial position or strategic direction. The company continues to focus on the commercialization of Ameluz and the expansion of its product pipeline.